Biofidelity’s assays can detect as little as a single molecule of mutated DNA against the background of billions of healthy molecules present in a typical patient sample.
With a simple workflow, fast turnaround time, and high sensitivity, this scalable platform chemistry can be automated and deployed on existing instruments in labs across the world.
Biofidelity’s proprietary chemistry has the demonstrated capability to detect large panels of mutations at <0.1% variant allele fraction (VAF), outperforming best-in-class sequencing tests in a fraction of the time and without the need for complex workflows or bioinformatics.
Our assays are designed to cover all the clinically actionable mutations recommended by testing guidelines from international cancer organisations including NCCN, ESMO, CAP, and AMP, while dramatically simplifying and accelerating workflows and reducing costs.
Through its simplicity and sensitivity, Biofidelity’s unique chemistry opens the possibility for routine monitoring of patients for treatment resistance and disease recurrence and the routine screening of at-risk populations.
We are working to enable broad access to the highest precision molecular diagnostics, allowing all oncologists to ensure that patients receive the right treatment at the right time, extending and improving the lives of patients.